Jiya, FDA ta Amurka ta sanar da amincewar Seattle Genetics' antibody-drug conjugate Adcetris (brentuximab vedotin) a hade tare da chemotherapy ga marasa lafiya tare da mataki na III ko IV classic Hodgkin's lymphoma (cHL). Wannan yarda ya wakilci ci gaba a cikin tsarin kulawa na farko don ingantaccen Hodgkin lymphoma wanda aka gabatar dashi cikin aikin asibiti fiye da shekaru 40 da suka gabata.
Lymphoma is a type of cancer that begins in the lymphatic system. The immune system helps the body fight infections and diseases. Lymphoma can develop almost anywhere in the body and can spread to nearby lymph nodes. It is divided into two types: Lymphoma na Hodgkin and non-Hodgkin lymphoma. Most patients with Hodgkin linzoma belong to the classic type. In this type of lymph node, there are large abnormal lymphocytes (a type of white blood cell). Called Reed-Sternberg cells. Through early intervention, patients with Hodgkin’s lymphoma usually get long-term remission.
A cikin gwaji na asibiti, damar Adcetris don magance lymphoma ta Hodgkin ta kasance ingantacciya-masu binciken sun tattara marasa lafiya 1,334 wadanda a baya suka karbi matsakaitan darussan 6 na zagayowar 28-rana kafin. Bayan haka, sun kasu kashi biyu, rukuni daya ya karɓi Adcetris da chemotherapy (AVD), ɗayan rukuni kuma ya sami chemotherapy kawai (ABVD). Nazarin ya nuna cewa marasa lafiya da ke karɓar maganin haɗin gwiwa suna da ƙananan ƙwayar cutar ta 23%, mutuwa, ko buƙatar fara sabon magani idan aka kwatanta da marasa lafiya waɗanda ke karɓar magani kawai.
Adcetris combines antibodies and drugs, allowing antibodies to direct drugs to kwayoyin lymphoma called CD30, approved for treatment of relapsed classic Hodgkin lymphoma, classic Hodgkin lymphoma with high risk of relapse or progression after stem cell transplantation, accepted Systemic anaplastic large cell lymphoma that other treatments are not effective, and primary cutaneous anaplastic large cell lymphoma that does not work with other treatments.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601935.htm
